4DMT presented positive interim data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting.
Carmot Therapeutics raised $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes.
Catalent Pharma announced that it has expanded its integrated development, manufacturing and supply solution, OneBio® Suite, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies, and mRNA.
Eureka Therapeutics was awarded a $10.6 Million CIRM Grant to support clinical trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer.
Gritstone Oncology announced the publication of interim results from an ongoing Phase 1 study evaluating their self-amplifying mRNA (samRNA) vaccines as a boost against #COVID19.
Kyverna Therapeutics was granted U.S. FDA Fast Track Designation for KYV-101 in Lupus Nephritis.
PhenomeX launched the Beacon Quest™ optofluidic system, with Opto® T Cell Profiling workflows for immunotherapy translational research.
Pivot Bio was named to the annual CNBC Disruptor 50 list, which highlights private companies that are chasing some of the market’s biggest opportunities, and growing despite a tough capital markets environment.
Sangamo Therapeutics received U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease.
UPSIDE Foods received official clearance from the U.S. Department of Agriculture (USDA) to commercially produce and sell their cell-cultivated chicken in the United States.
.
|